[
  {
    "id": "reg-kymriah-bla-001",
    "text_summary": "FDA approved Kymriah (tisagenlecleucel) on August 30, 2017, as the first-ever gene therapy approved in the United States. The BLA was granted for treatment of pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. The approval was based on the ELIANA global registrational trial (NCT02435849) which demonstrated an 83% overall remission rate (complete remission or complete remission with incomplete hematologic recovery) in 63 evaluable patients.",
    "product": "Kymriah (tisagenlecleucel)",
    "regulatory_event": "BLA",
    "date": "2017-08",
    "agency": "FDA",
    "indication": "Relapsed/refractory B-cell precursor ALL in patients up to 25 years of age",
    "decision": "approved",
    "conditions": "REMS program required for CRS and neurological toxicity management; 15-year long-term follow-up observational study for secondary malignancy monitoring; post-marketing commitment for RCR testing",
    "pivotal_trial": "ELIANA (NCT02435849)"
  },
  {
    "id": "reg-kymriah-bla-dlbcl-002",
    "text_summary": "FDA granted a supplemental BLA approval for Kymriah on May 1, 2018, expanding its indication to include adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Approval was based on the JULIET trial (NCT02445248), a single-arm, open-label, multicenter, phase II study demonstrating a 50% overall response rate (32% complete response) in 68 evaluable patients. This made Kymriah the first CAR-T therapy approved for two distinct indications.",
    "product": "Kymriah (tisagenlecleucel)",
    "regulatory_event": "BLA",
    "date": "2018-05",
    "agency": "FDA",
    "indication": "Relapsed/refractory DLBCL after two or more lines of systemic therapy",
    "decision": "approved",
    "conditions": "Same REMS program as initial approval; additional post-marketing requirement for DLBCL-specific long-term safety data collection",
    "pivotal_trial": "JULIET (NCT02445248)"
  },
  {
    "id": "reg-yescarta-bla-003",
    "text_summary": "FDA approved Yescarta (axicabtagene ciloleucel) on October 18, 2017, for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Approval was based on the ZUMA-1 trial (NCT02348216), which demonstrated a 72% overall response rate with 51% complete responses in 101 evaluable patients. Yescarta became the second CAR-T product and first CD28-costimulated CAR-T product approved by FDA.",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "regulatory_event": "BLA",
    "date": "2017-10",
    "agency": "FDA",
    "indication": "Relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy",
    "decision": "approved",
    "conditions": "REMS program for CRS and neurological toxicity management; 15-year long-term follow-up study; post-marketing requirement for RCR testing per retroviral vector guidance",
    "pivotal_trial": "ZUMA-1 (NCT02348216)"
  },
  {
    "id": "reg-tecartus-bla-004",
    "text_summary": "FDA granted accelerated approval to Tecartus (brexucabtagene autoleucel) on July 24, 2020, for treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Approval was based on the ZUMA-2 trial (NCT02601313), a single-arm, open-label, multicenter study that demonstrated an 87% overall response rate with 62% complete responses in 60 evaluable patients. Tecartus uses a T-cell enrichment step to remove circulating tumor cells prior to CAR-T manufacturing, distinguishing it from Yescarta.",
    "product": "Tecartus (brexucabtagene autoleucel)",
    "regulatory_event": "accelerated_approval",
    "date": "2020-07",
    "agency": "FDA",
    "indication": "Relapsed/refractory mantle cell lymphoma (MCL)",
    "decision": "approved",
    "conditions": "Accelerated approval based on ORR; confirmatory trial required; REMS program; 15-year long-term follow-up study for malignancy monitoring",
    "pivotal_trial": "ZUMA-2 (NCT02601313)"
  },
  {
    "id": "reg-breyanzi-bla-005",
    "text_summary": "FDA approved Breyanzi (lisocabtagene maraleucel) on February 5, 2021, for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Approval was based on the TRANSCEND NHL 001 trial (NCT02631044), which demonstrated a 73% overall response rate with 53% complete responses in 192 evaluable patients. Breyanzi is a defined composition CD4+/CD8+ CAR-T product administered at a fixed ratio, potentially reducing variability in clinical outcomes compared to other CAR-T products.",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "regulatory_event": "BLA",
    "date": "2021-02",
    "agency": "FDA",
    "indication": "Relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy",
    "decision": "approved",
    "conditions": "REMS program required; 15-year post-marketing long-term follow-up study; RCR testing requirements per lentiviral vector guidance",
    "pivotal_trial": "TRANSCEND NHL 001 (NCT02631044)"
  },
  {
    "id": "reg-abecma-bla-006",
    "text_summary": "FDA approved Abecma (idecabtagene vicleucel) on March 26, 2021, as the first BCMA-directed CAR-T cell therapy for treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. Approval was based on the KarMMa trial (NCT03361748), which demonstrated a 72% overall response rate with 28% complete responses in 128 evaluable patients at target dose levels. The median duration of response was 11.3 months.",
    "product": "Abecma (idecabtagene vicleucel)",
    "regulatory_event": "BLA",
    "date": "2021-03",
    "agency": "FDA",
    "indication": "Relapsed/refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody",
    "decision": "approved",
    "conditions": "REMS program for CRS and neurological toxicity management; 15-year long-term follow-up observational study; post-marketing requirement for RCR testing",
    "pivotal_trial": "KarMMa (NCT03361748)"
  },
  {
    "id": "reg-carvykti-bla-007",
    "text_summary": "FDA approved Carvykti (ciltacabtagene autoleucel) on February 28, 2022, for treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. Approval was based on the CARTITUDE-1 study (NCT03548207), which demonstrated a 98% overall response rate with 83% stringent complete responses in 97 evaluable patients. Carvykti targets two BCMA epitopes via its bispecific variable fragment design, providing a distinct binding mechanism.",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "regulatory_event": "BLA",
    "date": "2022-02",
    "agency": "FDA",
    "indication": "Relapsed/refractory multiple myeloma after four or more prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody",
    "decision": "approved",
    "conditions": "REMS program; 15-year long-term follow-up study; post-marketing studies for delayed neurotoxicity including Parkinsonism-like events and Guillain-Barre syndrome monitoring",
    "pivotal_trial": "CARTITUDE-1 (NCT03548207)"
  },
  {
    "id": "reg-kymriah-btd-008",
    "text_summary": "FDA granted Breakthrough Therapy Designation to tisagenlecleucel (CTL019) in July 2014 for treatment of relapsed/refractory pediatric ALL. This was among the first breakthrough therapy designations for a cell therapy product and was based on early clinical data from the University of Pennsylvania showing complete remission rates exceeding 90% in heavily pretreated pediatric ALL patients. The designation facilitated intensive FDA guidance throughout development and expedited review of the BLA.",
    "product": "Kymriah (tisagenlecleucel)",
    "regulatory_event": "breakthrough_therapy",
    "date": "2014-07",
    "agency": "FDA",
    "indication": "Relapsed/refractory pediatric ALL",
    "decision": "granted",
    "conditions": "Enhanced FDA interaction and rolling review eligibility; sponsor required to provide updated clinical data at regular intervals",
    "pivotal_trial": "Penn IND study / ELIANA (NCT02435849)"
  },
  {
    "id": "reg-yescarta-btd-009",
    "text_summary": "FDA granted Breakthrough Therapy Designation to axicabtagene ciloleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma. The designation was based on interim ZUMA-1 data showing an 82% overall response rate and 54% complete response rate in adult DLBCL patients who had failed two or more prior lines of therapy. This accelerated the development timeline and enabled rolling BLA submission.",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "regulatory_event": "breakthrough_therapy",
    "date": "2016-04",
    "agency": "FDA",
    "indication": "Relapsed/refractory diffuse large B-cell lymphoma",
    "decision": "granted",
    "conditions": "Rolling submission enabled; enhanced FDA interaction throughout development program; priority review eligibility",
    "pivotal_trial": "ZUMA-1 (NCT02348216)"
  },
  {
    "id": "reg-carvykti-btd-010",
    "text_summary": "FDA granted Breakthrough Therapy Designation to ciltacabtagene autoleucel in December 2019 for the treatment of relapsed or refractory multiple myeloma. The designation was based on extraordinary early-phase data from the LEGEND-2 study (NCT03090659) conducted in China, showing a 94% overall response rate and 68% stringent complete response rate in 74 patients. The bispecific BCMA-targeting design and deep response rates supported the breakthrough designation.",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "regulatory_event": "breakthrough_therapy",
    "date": "2019-12",
    "agency": "FDA",
    "indication": "Relapsed/refractory multiple myeloma",
    "decision": "granted",
    "conditions": "Enhanced FDA engagement; rolling review eligibility; expedited development timeline with Janssen/Legend Biotech",
    "pivotal_trial": "LEGEND-2 (NCT03090659) / CARTITUDE-1 (NCT03548207)"
  },
  {
    "id": "reg-kymriah-rmat-011",
    "text_summary": "FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to tisagenlecleucel for relapsed/refractory pediatric ALL. Kymriah was among the first products to receive RMAT designation under the 21st Century Cures Act (enacted December 2016), which created this new expedited pathway specifically for regenerative medicine therapies including cell therapies, gene therapies, and tissue-engineered products. RMAT designation provides all benefits of breakthrough therapy plus early interactions on expedited manufacturing development.",
    "product": "Kymriah (tisagenlecleucel)",
    "regulatory_event": "RMAT",
    "date": "2017-04",
    "agency": "FDA",
    "indication": "Relapsed/refractory pediatric ALL",
    "decision": "granted",
    "conditions": "All breakthrough therapy benefits plus early interactions regarding manufacturing development and potential for priority review; among first RMAT designations granted under 21st Century Cures Act",
    "pivotal_trial": "ELIANA (NCT02435849)"
  },
  {
    "id": "reg-yescarta-rmat-012",
    "text_summary": "FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to axicabtagene ciloleucel for treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Yescarta was among the earliest CAR-T products to receive RMAT designation alongside Kymriah, recognizing the transformative potential of CD19-directed CAR-T therapy in hematologic malignancies. The RMAT pathway enabled Kite Pharma to engage with FDA early on manufacturing scale-up and process validation.",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "regulatory_event": "RMAT",
    "date": "2017-05",
    "agency": "FDA",
    "indication": "Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma",
    "decision": "granted",
    "conditions": "Enhanced manufacturing interactions with CBER; all benefits of breakthrough therapy designation; priority review eligible",
    "pivotal_trial": "ZUMA-1 (NCT02348216)"
  },
  {
    "id": "reg-cart-rems-crs-013",
    "text_summary": "FDA required a Risk Evaluation and Mitigation Strategy (REMS) for all approved CD19-directed CAR-T products due to the risk of cytokine release syndrome (CRS) and neurological toxicities. The REMS programs require healthcare facilities dispensing CAR-T therapies to be specially certified, with staff trained in CRS recognition and management. Tocilizumab must be available on-site for immediate administration. The REMS requires monitoring patients at certified healthcare facilities for a minimum of 7 days following CAR-T infusion.",
    "product": "General CAR-T regulatory",
    "regulatory_event": "REMS",
    "date": "2017-08",
    "agency": "FDA",
    "indication": "All approved CAR-T indications",
    "decision": "required",
    "conditions": "Certified healthcare facility requirement; staff training in CRS/ICANS management; tocilizumab on-site availability (minimum 2 doses per patient); patient enrollment in REMS registry; at least 7-day post-infusion monitoring",
    "pivotal_trial": "ELIANA, ZUMA-1, JULIET (collective safety data)"
  },
  {
    "id": "reg-bcma-rems-014",
    "text_summary": "FDA required distinct REMS programs for BCMA-directed CAR-T products (Abecma and Carvykti) that include additional monitoring requirements beyond CD19-directed products. These REMS address CRS, neurological toxicities including ICANS, and for Carvykti specifically, delayed neurotoxicity events including Parkinsonism-like symptoms, Guillain-Barre syndrome, and cranial nerve palsies. The REMS programs mandate extended monitoring periods and specialized neurological assessments.",
    "product": "General CAR-T regulatory",
    "regulatory_event": "REMS",
    "date": "2021-03",
    "agency": "FDA",
    "indication": "Relapsed/refractory multiple myeloma (BCMA-directed CAR-T products)",
    "decision": "required",
    "conditions": "Certified healthcare facility requirement; extended neurological monitoring for delayed neurotoxicity; healthcare provider training specific to BCMA-directed CAR-T toxicities; patient monitoring for movement and neurocognitive disorders",
    "pivotal_trial": "KarMMa (NCT03361748), CARTITUDE-1 (NCT03548207)"
  },
  {
    "id": "reg-cart-label-tmalignancy-015",
    "text_summary": "In November 2023, FDA required updated boxed warnings for all six approved CAR-T cell immunotherapies regarding the risk of T-cell malignancies, including T-cell lymphoma, following CAR-T treatment. FDA identified reports of T-cell malignancies in patients treated with BCMA-directed and CD19-directed CAR-T products, some occurring as early as months after treatment. The updated labeling specifies that T-cell malignancies have occurred in patients treated with these products and that lifelong monitoring is recommended.",
    "product": "General CAR-T regulatory",
    "regulatory_event": "label_update",
    "date": "2023-11",
    "agency": "FDA",
    "indication": "All approved CAR-T indications",
    "decision": "updated",
    "conditions": "Boxed warning added to all six approved CAR-T product labels; lifelong monitoring for secondary malignancies recommended; FDA continuing to investigate causal relationship between CAR-T and T-cell malignancies",
    "pivotal_trial": "Post-marketing surveillance (FAERS database)"
  },
  {
    "id": "reg-breyanzi-label-2l-016",
    "text_summary": "FDA approved a supplemental BLA for Breyanzi (lisocabtagene maraleucel) in June 2022, expanding its indication to include adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapsing within 12 months. This made Breyanzi the first CAR-T therapy approved for second-line LBCL. The approval was based on the TRANSFORM trial (NCT03575351), which demonstrated superior event-free survival compared to standard-of-care salvage chemotherapy followed by autologous stem cell transplant.",
    "product": "Breyanzi (lisocabtagene maraleucel)",
    "regulatory_event": "label_update",
    "date": "2022-06",
    "agency": "FDA",
    "indication": "Second-line large B-cell lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy",
    "decision": "approved",
    "conditions": "Updated prescribing information to include second-line LBCL indication; continued REMS and long-term follow-up requirements",
    "pivotal_trial": "TRANSFORM (NCT03575351)"
  },
  {
    "id": "reg-carvykti-label-earlier-017",
    "text_summary": "FDA approved a supplemental BLA for Carvykti (ciltacabtagene autoleucel) in April 2024, expanding its indication to include adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This approval moved Carvykti to earlier-line multiple myeloma treatment. The CARTITUDE-4 trial (NCT04181827) demonstrated superior progression-free survival versus standard-of-care (pomalidomide-bortezomib-dexamethasone or daratumumab-pomalidomide-dexamethasone).",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "regulatory_event": "label_update",
    "date": "2024-04",
    "agency": "FDA",
    "indication": "Relapsed/refractory multiple myeloma after at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent",
    "decision": "approved",
    "conditions": "Updated prescribing information for earlier-line MM indication; continued REMS; additional post-marketing study requirement for confirmatory long-term PFS data",
    "pivotal_trial": "CARTITUDE-4 (NCT04181827)"
  },
  {
    "id": "reg-kymriah-ema-018",
    "text_summary": "The European Medicines Agency (EMA) granted conditional marketing authorization for Kymriah (tisagenlecleucel) in August 2018 for two indications: pediatric and young adult patients up to 25 years of age with B-cell ALL that is refractory, in post-transplant relapse, or in second or later relapse; and adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. The CHMP positive opinion was based on the same ELIANA and JULIET datasets submitted to FDA, with additional EU-specific pharmacovigilance requirements.",
    "product": "Kymriah (tisagenlecleucel)",
    "regulatory_event": "full_approval",
    "date": "2018-08",
    "agency": "EMA",
    "indication": "r/r B-ALL (up to 25 years) and r/r DLBCL after two or more lines of systemic therapy",
    "decision": "approved",
    "conditions": "Conditional marketing authorization; EU-specific pharmacovigilance plan; qualified treatment center certification required; annual benefit-risk re-evaluation",
    "pivotal_trial": "ELIANA (NCT02435849), JULIET (NCT02445248)"
  },
  {
    "id": "reg-yescarta-ema-019",
    "text_summary": "The European Medicines Agency granted conditional marketing authorization for Yescarta (axicabtagene ciloleucel) in August 2018, for treatment of adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy. The EMA approval followed the FDA approval by approximately 10 months. Qualified treatment centers in EU member states were required to undergo certification and training programs before administering Yescarta.",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "regulatory_event": "full_approval",
    "date": "2018-08",
    "agency": "EMA",
    "indication": "Relapsed/refractory DLBCL and primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy",
    "decision": "approved",
    "conditions": "Conditional marketing authorization; qualified treatment center requirement; EU pharmacovigilance plan including 15-year long-term follow-up; annual renewal required",
    "pivotal_trial": "ZUMA-1 (NCT02348216)"
  },
  {
    "id": "reg-carvykti-ema-020",
    "text_summary": "The European Medicines Agency granted conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) in May 2022, approximately three months after FDA approval. The EMA approved Carvykti for treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. The CHMP noted the exceptional response rates from CARTITUDE-1 and mandated enhanced pharmacovigilance for delayed neurotoxicity events.",
    "product": "Carvykti (ciltacabtagene autoleucel)",
    "regulatory_event": "full_approval",
    "date": "2022-05",
    "agency": "EMA",
    "indication": "Relapsed/refractory multiple myeloma after at least three prior therapies",
    "decision": "approved",
    "conditions": "Conditional marketing authorization; enhanced pharmacovigilance for delayed neurotoxicity (Parkinsonism, GBS, cranial nerve palsies); qualified treatment center certification; annual benefit-risk review",
    "pivotal_trial": "CARTITUDE-1 (NCT03548207)"
  },
  {
    "id": "reg-kymriah-pmr-rcr-021",
    "text_summary": "As a condition of BLA approval, FDA required Novartis to conduct a 15-year post-marketing observational study for all Kymriah-treated patients to monitor for replication-competent lentivirus (RCL), insertional oncogenesis, and secondary malignancies. The study protocol requires annual patient blood sample collection with archiving and RCL PCR testing. Per FDA guidance for lentiviral vector gene therapies, RCL testing must be performed at baseline, 3, 6, and 12 months post-infusion, then annually for 15 years.",
    "product": "Kymriah (tisagenlecleucel)",
    "regulatory_event": "post_marketing_requirement",
    "date": "2017-08",
    "agency": "FDA",
    "indication": "All Kymriah-approved indications",
    "decision": "required",
    "conditions": "15-year observational follow-up; annual RCL testing; blood sample archiving; annual safety reports to FDA; monitoring for insertional oncogenesis and secondary malignancies including T-cell lymphoma",
    "pivotal_trial": "ELIANA (NCT02435849), JULIET (NCT02445248)"
  },
  {
    "id": "reg-yescarta-pmr-ltfu-022",
    "text_summary": "FDA required Kite/Gilead to conduct a 15-year long-term follow-up (LTFU) study for all Yescarta-treated patients as a post-marketing requirement. Because Yescarta utilizes a gamma-retroviral vector, replication-competent retrovirus (RCR) testing is mandated per FDA guidance. The LTFU protocol includes annual monitoring for delayed adverse events, secondary malignancies, hematologic disorders, autoimmune disorders, and new neurological events. Samples must be archived and available for integration site analysis if secondary malignancies occur.",
    "product": "Yescarta (axicabtagene ciloleucel)",
    "regulatory_event": "post_marketing_requirement",
    "date": "2017-10",
    "agency": "FDA",
    "indication": "All Yescarta-approved indications",
    "decision": "required",
    "conditions": "15-year LTFU study; annual RCR testing specific to retroviral vector; sample archiving for potential integration site analysis; annual safety reports; monitoring for delayed adverse events and secondary malignancies",
    "pivotal_trial": "ZUMA-1 (NCT02348216)"
  },
  {
    "id": "reg-abecma-pmr-myeloma-023",
    "text_summary": "FDA required Bristol Myers Squibb/2seventy bio to conduct post-marketing studies evaluating long-term safety and efficacy of Abecma in relapsed/refractory multiple myeloma. The required studies include a 15-year long-term follow-up for secondary malignancy monitoring and RCL testing, and a confirmatory study comparing Abecma to standard of care in earlier-line multiple myeloma (KarMMa-3, NCT03651128). The KarMMa-3 study subsequently demonstrated superior PFS versus standard regimens, supporting continued benefit-risk assessment.",
    "product": "Abecma (idecabtagene vicleucel)",
    "regulatory_event": "post_marketing_requirement",
    "date": "2021-03",
    "agency": "FDA",
    "indication": "Relapsed/refractory multiple myeloma",
    "decision": "required",
    "conditions": "15-year LTFU study for secondary malignancies and RCL monitoring; confirmatory KarMMa-3 trial required; annual safety reports to CBER; sample archiving for integration site analysis if malignancy detected",
    "pivotal_trial": "KarMMa (NCT03361748), KarMMa-3 (NCT03651128)"
  },
  {
    "id": "reg-fda-guidance-cgtp-024",
    "text_summary": "FDA's Center for Biologics Evaluation and Research (CBER) published the final guidance document 'Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products' in March 2022. This guidance addresses key topics including CAR construct design considerations, manufacturing process development for autologous products, preclinical study design, clinical trial design, and potency assay development. The guidance recommends functional potency assays measuring cytotoxicity and cytokine release, along with identity testing for CAR expression by flow cytometry.",
    "product": "General CAR-T regulatory",
    "regulatory_event": "BLA",
    "date": "2022-03",
    "agency": "FDA",
    "indication": "All CAR-T product development",
    "decision": "approved",
    "conditions": "Non-binding guidance document; recommends potency assays measuring cytotoxicity and cytokine release; addresses out-of-specification product disposition; recommends early CBER engagement on CMC and release testing strategy",
    "pivotal_trial": "N/A (guidance document)"
  },
  {
    "id": "reg-fda-guidance-ltfu-025",
    "text_summary": "FDA published updated guidance 'Long Term Follow-up After Administration of a Gene Therapy Product' in January 2020, establishing the framework for 15-year post-treatment monitoring of gene therapy and gene-modified cell therapy products including all CAR-T therapies. The guidance specifies that integrating vectors (lentiviral and retroviral) require 15-year follow-up with annual monitoring, while non-integrating vectors may warrant shorter follow-up. Monitoring includes assessment for new malignancies, hematologic disorders, neurological disorders, autoimmune disorders, and new infections. Annual patient samples must be archived for potential future vector analysis.",
    "product": "General CAR-T regulatory",
    "regulatory_event": "BLA",
    "date": "2020-01",
    "agency": "FDA",
    "indication": "All gene therapy and CAR-T products",
    "decision": "approved",
    "conditions": "15-year follow-up for integrating vectors; annual monitoring visits; sample archiving requirements; delayed adverse event reporting; RCL/RCR testing schedules specified by vector type; guidance applicable to all INDs and BLAs for gene therapies",
    "pivotal_trial": "N/A (guidance document)"
  }
]
